GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B

January 17, 2018

Responsive image

YONGIN, South Korea, Jan. 17, 2018 /PRNewswire/ — GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 clinical trial for GC1102 (also known as Hepabig-gene), the company’s inve…

Category: Precious Metals